Back to Newsroom
Back to Newsroom

Innovus Pharmaceuticals to Present at LD Micro Conference in Los Angeles on December 2, 2014

Wednesday, 26 November 2014 06:00 AM

Topic:

San Diego, CA / ACCESSWIRE / November 26, 2014 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma"), (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective non-prescription over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it will be presenting at the LD Micro Conference held in Los Angeles, CA from December 2 - 4, 2014.

Event: LD Micro Conference
Location: Luxe Bel Air Hotel, Los Angeles
Date: Tuesday, December 2, 2014
Time: 2:30 PM (PT)

Management will deliver a presentation and provide an overview of Innovus Pharma's business operations and recent updates on the Company including commercial partnerships signed for some of its products for distribution in 28 countries. The Company's products include:

1. Zestra(R): clinically proven to increase desire and arousal in women

2. EjectDelay(R) :indicated for the treatment of premature ejaculation

3. Sensum+(R): to increase penile sensitivity

4. Vesele(R):to boost sexual and cognitive health

5. Zestra Glide(R):, the only high viscosity, low osmolality water based lubricant

In addition to the presentation, management will be available for one-on-one meetings.

To arrange a meeting with management, please contact Lynnette Dillen EVP and CFO at [email protected].

More information on Innovus Pharma can be found on www.innovuspharma.com; www.zestra.com, www.ejectdelay.com, www.myvesele.com and on Innovus' Public Profile on Interlinked.com.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra(R) clinically proven to increase arousal and desire,EjectDelay(R) for premature ejaculation, and has a total of five marketed products in this space, including Sensum+(R) (for sales outside the U.S. only), Zestra Glide(R) and Vesele(R) for increasing blood flow to enhance sexual and mental health.

For more information, go to www.innovuspharma.com

Innovus Pharma's Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra(R), to successfully commercialize such products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

###

Innovus Pharma Contact:

Kevin Holmes
Chesapeake Group
[email protected]
T: 410-825-3930

 

SOURCE: Innovus Pharmaceuticals, Inc.

Topic:
Back to newsroom
Back to Newsroom
Share by: